TET Gene Loss Triggered Recurrent Chromosome Trisomy
Researchers identified that deficient DNA demethylation pathways drive aneuploidy in lymphoid cells.
Updated on Oct. 1, 2026 in Life Sciences
Analysis published on October 1, 2026, revealed that the loss of TET enzymes causes recurring chromosome 17 trisomy in iNKT cells. This research-stage finding demonstrates how disrupted genetic regulatory pathways facilitate the selection of aneuploid states during cell expansion.
Why it matters
Understanding how epigenetic regulators like TET and DNMT3A shape karyotypic evolution provides critical insight into the mechanisms behind aggressive tumor growth. This work clarifies how loss-of-function mutations in methylation pathways enable cellular populations to rapidly acquire and enrich for chromosomal abnormalities.
Single-cell whole-genome sequencing confirmed that iNKT cells exhibit chromosome 17 trisomy, while inducible Tet-deficient mouse embryonic stem cells selected for chromosome 6 trisomy. These results indicate a systematic selection for aneuploid states when DNA methylation or demethylation is disrupted.
The players
TET enzymes
A family of proteins that perform DNA demethylation and serve as key epigenetic regulators of cell development.
DNMT3A
A DNA methyltransferase enzyme involved in the epigenetic maintenance of the genome.
The details
TET (Ten-eleven translocation) enzymes are proteins that facilitate DNA demethylation, a process that removes methyl groups from DNA to regulate gene expression. When these enzymes are lost, the cell struggles to maintain genomic stability during stress, such as antigen or IL-2 stimulation. The study tracked iNKT cells—specialized immune cells that bridge innate and adaptive immunity—and found that the absence of TET allows aneuploid cells, those with an abnormal number of chromosomes, to outcompete normal cells during expansion.
Timeline
October 1, 2026: The research findings were published.
The Tech Race
This study extends the foundation of the Cancer Genome Atlas (TCGA) by shifting focus from static mutation mapping to the active, process-driven evolution of karyotypes in response to epigenetic loss. It follows established research into DNMT3A deficiency, placing TET-mediated pathways as a central mechanism in the field of cancer genome evolution.
This finding currently exists in research-stage mouse models and does not offer immediate diagnostic or therapeutic applications. Scientists and researchers in oncology will utilize these mechanisms to better interpret genomic data from patients with lymphoid malignancies.
The takeaway
The research establishes that epigenetic enzyme loss is a primary driver of chromosomal aneuploidy rather than a secondary byproduct of cancer. Future inquiries should focus on identifying whether pharmacological intervention can restore methylation balance to stall the selection of these trisomic clones.
Further reading
For broader context on current investigations into cellular genomics, visit Life Sciences.
Source note: This article includes information reported by Biorxiv.
